Treat ER+ight: Treatment of Canadian postmenopausal women with ER+ HER2- advanced breast cancer in the real-world setting with hormone therapy ± targeted therapy.

Abstract

TPS614Background: Although randomized controlled trials (RCTs) provide evidence of efficacy, generalization of these results to patients in the real-world setting is challenging, given RCTs are conducted in highly selected patient populations. An understanding of the effectiveness and safety of approved cancer therapies in routine clinical practice is essential in order to optimize the management of these patients and to identify treatment and safety gaps. Treat ER+ight is the first Canadian study to describe real-world treatment patterns/sequencing, effectiveness and safety for postmenopausal HR+HER2- advanced breast cancer (aBC) patients. Methods: This registry incorporates an observational prospective cohort design and will enroll 320 postmenopausal HR+HER2- aBC women that have been previously exposed to non-steroidal aromatase inhibitor (NSAI) therapy being treated with: endocrine therapy (ET) alone or ET in combination with targeted therapy (ET+TT). Patients who are receiving chemotherapy, have had >...